Enlivex Therapeutics Ltd. (NASDAQ:ENLV) is expected to post earnings of -$0.28 per share

Wall Street analysts expect Enlivex Therapeutics Ltd. (NASDAQ:ENLV) reports earnings of ($0.28) per share for the current fiscal quarter, Zacks reports. Zero analysts provided earnings estimates for Enlivex Therapeutics. Enlivex Therapeutics reported earnings per share of ($0.43) in the same quarter last year, suggesting a positive year-over-year growth rate of 34.9%. The company is expected to release its next quarterly results on Friday, April 29.

According to Zacks, analysts expect Enlivex Therapeutics to report annual earnings of $0.86 per share for the current year. For the next fiscal year, analysts expect the company to post earnings of ($1.54) per share. Zacks Investment Research’s EPS calculations are an average average based on a survey of sell-side research companies that track Enlivex Therapeutics.

Enlivex Therapeutics (NASDAQ:ENLV) last released its quarterly earnings data on Sunday, November 21. The company reported ($0.19) earnings per share (EPS) for the quarter, beating Thomson Reuters consensus estimate of ($0.21) by $0.02.

A number of stock analysts have weighed in on ENLV shares. Zacks Investment Research downgraded Enlivex Therapeutics from a “buy” rating to a “hold” rating in a Tuesday, October 12 research report. HC Wainwright reaffirmed a “buy” rating and set a price target of $33.00 on Enlivex Therapeutics shares in a Tuesday, October 5 research report.

Shares of ENLV traded at $0.20 on Friday, reaching $5.15. The company’s stock had a trading volume of 56,928 shares, compared to an average volume of 80,796. The company’s fifty-day moving average price is $6.25 and its 200-day moving average price is $8.37. Enlivex Therapeutics has a fifty-two week low of $4.82 and a fifty-two week high of $29.40. The company has a market capitalization of $94.30 million, a price-earnings ratio of -5.26 and a beta of 1.13.

(A d)

There are not many days left on the calendar…and yet the global semiconductor market has reached $466.2 billion – despite the pandemic.

Even better, the chip shortage has created huge opportunities for recurring hits.

These four tech companies are well positioned to take advantage of this rapidly growing demand.

A number of large investors have recently increased or reduced their stakes in the company. Wells Fargo & Company MN increased its holdings of Enlivex Therapeutics shares by 8.3% in Q2. Wells Fargo & Company MN now owns 19,491 shares of the company valued at $174,000 after purchasing an additional 1,500 shares in the last quarter. UBS Group AG increased its equity stake in Enlivex Therapeutics by 15.2% in the third quarter. UBS Group AG now owns 15,454 shares of the company valued at $152,000 after buying an additional 2,034 shares in the last quarter. Morgan Stanley increased its holdings of Enlivex Therapeutics shares by 31.5% in the third quarter. Morgan Stanley now owns 18,543 shares of the company valued at $183,000 after buying 4,441 additional shares in the last quarter. Compagnie Lombard Odier SCmA increased its stake in Enlivex Therapeutics shares by 40.0% in the 3rd quarter. Compagnie Lombard Odier SCmA now owns 35,000 shares of the company valued at $353,000 after purchasing an additional 10,000 shares in the last quarter. Finally, Geode Capital Management LLC acquired a new equity stake in Enlivex Therapeutics in Q3 valued at approximately $102,000. 4.63% of the shares are held by hedge funds and other institutional investors.

About Enlivex Therapeutics

Enlivex Therapeutics Ltd. is developing a pipeline of autologous and allogeneic drugs for the treatment of autoimmune and inflammatory conditions. It produces treatment devices for CAR-T cancer treatment procedures, graft versus host disease resulting from bone marrow transplants, solid organ transplants and a range of autoimmune and inflammatory diseases, such as as Crohn’s disease, rheumatoid arthritis, gout, multiple sclerosis and other disorders.

Feature Article: Trading Stops Explained

Get a Free Copy of Zacks Research Report on Enlivex Therapeutics (ENLV)

For more information on Zacks Investment Research’s research offerings, visit Zacks.com

This instant alert was powered by MarketBeat’s narrative science technology and financial data to provide readers with the fastest and most accurate reports. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send questions or comments about this story to [email protected]

Should you invest $1,000 in Enlivex Therapeutics right now?

Before you consider Enlivex Therapeutics, you’ll want to hear this.

MarketBeat tracks Wall Street’s top-rated, top-performing research analysts daily and the stocks they recommend to their clients. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the market takes off…and Enlivex Therapeutics was not on the list.

While Enlivex Therapeutics currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.

See the 5 actions here